Iradimed (IRMD) AI Stock Analysis

Compare

161 Followers

Top Page

Iradimed

(NASDAQ:IRMD)

Rating:80Outperform

Price Target:

$81.00

▲(11.43% Upside)

Iradimed's strong financial performance and positive earnings call sentiment are the primary drivers of its high score. Technical indicators suggest positive momentum, though caution is advised due to potential overvaluation and overbought signals. Corporate governance decisions further support the company's strategic direction.

Iradimed (IRMD) vs. SPDR S&P 500 ETF (SPY)

Market Cap

$924.62M

Dividend Yield0.89%

Average Volume (3M)53.02K

Price to Earnings (P/E)44.3

Beta (1Y)0.81

Revenue Growth11.73%

EPS Growth10.27%

CountryUS

Employees160

SectorHealthcare

Sector Strength47

IndustryMedical - Devices

Share Statistics

EPS (TTM)0.49

Shares Outstanding12,720,002

10 Day Avg. Volume60,665

30 Day Avg. Volume53,025

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.77

Enterprise Value/Revenue9.20

Enterprise Value/Gross Profit11.96

Enterprise Value/Ebitda26.76

Forecast

1Y Price Target

$74.33

Price Target Upside2.26% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering3

Iradimed Business Overview & Revenue Model

Company DescriptionIradimed Corporation (IRMD) is a medical technology company specializing in innovative solutions for the healthcare sector, particularly in the field of MRI (Magnetic Resonance Imaging). The company is known for developing advanced MRI-compatible products, including its flagship product, the MRI-compatible infusion pump. Iradimed's offerings enhance patient safety and comfort while providing healthcare professionals with tools to improve diagnostic quality and operational efficiency.

How the Company Makes MoneyIradimed generates revenue primarily through the sale of its MRI-compatible infusion pumps and associated disposables. The company’s revenue model is centered around the direct sale of these medical devices to hospitals and healthcare facilities, which often require ongoing maintenance and support. Additionally, Iradimed benefits from recurring revenue through the sale of disposable components that accompany their infusion pumps. Strategic partnerships with healthcare providers and distributors, along with a focus on expanding their product line and entering new markets, further contribute to their earnings. The company also invests in research and development to innovate and enhance their product offerings, ensuring a competitive edge and sustained revenue growth.

Iradimed Earnings Call Summary

Earnings Call Date:Aug 01, 2025

(Q2-2025)

% Change Since: |

Next Earnings Date:Oct 31, 2025

Earnings Call Sentiment Positive

The earnings call highlighted record-breaking revenue and growth, strong product performance, and successful FDA clearance for a new product, indicating a positive outlook. However, challenges such as declining international sales and operational inefficiencies during the facility transition present some concerns. Overall, the positive aspects significantly outweigh the negatives.

Q2-2025 Updates

Positive Updates

Record-Breaking Revenue and Growth

Achieved revenue of $20.4 million in Q2 2025, a 14% increase over the same period last year, marking the 16th consecutive quarter of record revenues. GAAP diluted earnings per share increased 18% from Q2 of 2024.

Strong Product Performance

MRI IV pump systems contributed $8.2 million, up 19% year-over-year, and patient vital signs monitoring systems contributed $5.9 million, up 9%.

FDA Clearance for New Product

The FDA cleared the new 3870 IV pump systems for distribution, marking a significant milestone for the company.

Positive Financial Guidance

For Q3 2025, expected revenue of $20.5 million to $20.9 million, representing 12% to 14% growth over Q3 2024. For the full year 2025, revenue is expected to be $80 million to $82.5 million, up from prior guidance of $78 million to $82 million.

Strong Cash Flow and Financial Position

Cash and cash equivalents of $53 million, with a strong cash flow from operations of $7.7 million for the quarter, up 17% from Q2 2024.

Negative Updates

International Sales Decline

International sales decreased 9% to $2.2 million, contributing to 11% of total revenue, down from 14% in Q2 2024.

Operational Inefficiencies During Transition

Anticipated short-lived operational inefficiencies during the facility transition, which could temper earnings growth in the near term.

Company Guidance

During the IRADIMED CORPORATION's second-quarter 2025 earnings call, the company provided updated guidance indicating strong growth expectations. For the third quarter of 2025, they anticipate revenue between $20.5 million and $20.9 million, reflecting a 12% to 14% increase over the same period in 2024. They also expect GAAP diluted earnings per share to range from $0.41 to $0.45, with non-GAAP EPS projected between $0.45 and $0.49. For the full year of 2025, IRADIMED has increased its revenue guidance to $80 million to $82.5 million, representing a 9% to 13% growth over 2024's $73.2 million revenue. The GAAP diluted EPS is expected to be between $1.60 and $1.70, while non-GAAP EPS is projected to be between $1.76 and $1.86. This updated guidance takes into account approximately $2.6 million in stock-related compensation expense for the year. The company remains committed to delivering shareholder value with a $0.17 per share quarterly dividend declared for Q3 2025.

Iradimed Financial Statement Overview

Summary

Iradimed demonstrates strong financial performance with robust revenue growth, high gross profit margins, and a solid balance sheet with minimal debt. Cash flow generation is consistent, although net profit margins and capital expenditures could be optimized further.

Income Statement

Very Positive

Iradimed has demonstrated robust revenue growth with a 41.0% increase from 2022 to 2023 and a further 14.0% increase in 2024. Gross profit margins have remained strong, averaging around 77% over recent periods. The company maintains healthy EBIT and EBITDA margins, showcasing strong operational efficiency and profitability. However, the net profit margin, while solid, indicates room for further optimization.

Balance Sheet

Very Positive

The balance sheet of Iradimed is very healthy, with a remarkably low debt-to-equity ratio, indicating minimal leverage risk. The equity ratio is strong, reflecting a robust balance of equity to total assets. ROE is impressive, showing efficient use of equity to generate profits. Overall, the company has a solid financial position with low liabilities relative to equity.

Cash Flow

Positive

Iradimed shows a positive cash flow trend, with stable free cash flow generation despite fluctuations in capital expenditures. The operating cash flow to net income ratio is strong, indicating efficient cash conversion from profits. The free cash flow to net income ratio is consistent, though recent capital expenditures have slightly impacted free cash flow growth.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	77.64M	73.24M	65.56M	53.30M	41.81M	31.72M
Gross Profit	59.75M	56.35M	50.16M	41.28M	32.05M	23.57M
EBITDA	26.70M	22.78M	20.80M	16.30M	11.22M	3.28M
Net Income	20.66M	19.23M	17.19M	12.83M	9.33M	1.37M
Balance Sheet
Total Assets	106.45M	98.33M	92.16M	85.51M	82.88M	71.07M
Cash, Cash Equivalents and Short-Term Investments	53.00M	52.23M	49.76M	57.96M	62.50M	51.98M
Total Debt	0.00	154.69K	2.04M	2.21M	2.48M	2.72M
Total Liabilities	12.15M	11.51M	20.74M	11.84M	10.71M	9.68M
Stockholders Equity	94.30M	86.82M	71.42M	73.67M	72.17M	61.38M
Cash Flow
Free Cash Flow	13.55M	17.62M	5.46M	8.17M	10.52M	5.18M
Operating Cash Flow	27.14M	25.62M	13.47M	10.04M	11.26M	5.82M
Investing Cash Flow	-13.81M	-8.82M	-8.01M	-1.37M	648.24K	246.97K
Financing Cash Flow	-8.87M	-14.34M	-13.66M	-12.71M	24.43K	522.48K

Iradimed Technical Analysis

Technical Analysis Sentiment

Positive

Last Price72.69

Price Trends

50DMA

62.74

Positive

100DMA

58.21

Positive

200DMA

56.56

Positive

Market Momentum

MACD

2.94

Positive

RSI

69.08

Neutral

STOCH

71.59

Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IRMD, the sentiment is Positive. The current price of 72.69 is above the 20-day moving average (MA) of 69.10, above the 50-day MA of 62.74, and above the 200-day MA of 56.56, indicating a bullish trend. The MACD of 2.94 indicates Positive momentum. The RSI at 69.08 is Neutral, neither overbought nor oversold. The STOCH value of 71.59 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IRMD.

Iradimed Risk Analysis

Iradimed disclosed 36 risk factors in its most recent earnings report. Iradimed reported the most risks in the "Finance & Corporate" category.

Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added 0 New Risks

Iradimed Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
IRMD	80 Outperform	$924.62M	44.34	23.75%	0.89%	11.73%	10.27%
SIBN	63 Neutral	$708.37M	―	-14.18%	―	22.93%	43.83%
BVS	58 Neutral	$601.08M	―	-0.10%	―	5.08%	99.38%
CBLL	52 Neutral	$420.17M	―	26.25%	―	―	―
Sector *	51 Neutral	$7.83B	-0.18	-40.10%	2.29%	21.46%	-2.03%
AVNS	48 Neutral	$537.34M	45.80	-46.17%	―	1.48%	-6091.13%
RXST	47 Neutral	$347.79M	―	-11.66%	―	27.68%	20.87%

* Healthcare Sector Average

Performance Comparison

IRMD

Iradimed

72.69

26.22

56.42%

AVNS

Avanos Medical

11.87

-12.27

-50.83%

SIBN

SI-Bone

16.59

0.28

1.72%

BVS

Bioventus

7.49

-2.39

-24.19%

RXST

RxSight

8.55

-46.92

-84.59%

CBLL

Ceribell, Inc.

11.60

-13.90

-54.51%

Iradimed Corporate Events

Executive/Board ChangesShareholder Meetings

Iradimed Holds Annual Stockholders Meeting, Key Decisions Made

Positive

Jun 23, 2025

On June 19, 2025, Iradimed Corporation held its Annual Meeting of Stockholders, where several key decisions were made. Stockholders elected five directors to the Board, ratified RSM US LLP as the independent auditor for 2025, and approved an advisory resolution on executive compensation. These outcomes reflect shareholder support for the company’s leadership and strategic direction, potentially impacting its governance and operational oversight.

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Aug 19, 2025